<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857856</url>
  </required_header>
  <id_info>
    <org_study_id>TCC2012007</org_study_id>
    <secondary_id>2013-001067-23</secondary_id>
    <nct_id>NCT01857856</nct_id>
  </id_info>
  <brief_title>PHOspholamban RElated CArdiomyopathy STudy - Intervention</brief_title>
  <acronym>i-PHORECAST</acronym>
  <official_title>PHOspholamban RElated CArdiomyopathy STudy - Intervention (Efficacy Study of Eplerenone in Presymptomaticphospholamban R14del Carriers)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.p. van den Berg, MD, PhD, professor in Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Interuniversity Cardiology Institute of the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Netherlands: CVON, CardioVascular Research Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phospholamban (PLN) R14del mutation carriers may develop dilated cardiomyopathy (DCM) and/or
      arrhythmmogenic cardiomyopathy (ACM). Analogous to other inherited cardiomyopathies, the
      natural course of the disease is age-related (&quot;age-related penetrance&quot;); after a
      presymptomatic phase of variable length many PLN R14del-carriers progress to overt disease,
      and are diagnosed with either DCM or ARVC. PLN is a regulator of the sarcoplasmic reticulum
      Ca2+-ATPase (SERCA2a) pump in cardiac muscle and thereby important for maintaining Ca2+
      homeostasis. Cardiac fibrosis appears to be an early manifestation of disease. The
      investigators hypothesize that treatment of presymptomatic PLN R14del-carriers with
      eplerenone, which by virtue of its mineralocorticoid(aldosterone)-blocking properties is a
      strong antifibrotic agent, reduces disease progression and postpones onset of overt disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Netherlands ≈15% of idiopathic dilated cardiomyopathy (DCM) and ≈10% arrhythmogenic
      right ventricular cardiomyopathy (ARVC) patients carry a single (founder) mutation in the
      gene encoding Phospholamban, PLN R14del. Analogous to other inherited cardiomyopathies, the
      natural course of the disease is age-related (&quot;age-related penetrance&quot;); after a
      presymptomatic phase of variable length many PLN R14del-carriers progress to overt disease,
      and are diagnosed with either DCM or ARVC. PLN is a regulator of the sarcoplasmic reticulum
      Ca2+-ATPase (SERCA2a) pump in cardiac muscle and thereby important for maintaining Ca2+
      homeostasis. Cardiac fibrosis appears to be an early manifestation of disease. The
      investigators hypothesize that treatment of presymptomatic PLN R14del-carriers with
      eplerenone, which by virtue of its mineralocorticoid(aldosterone)-blocking properties is a
      strong antifibrotic agent, reduces disease progression and postpones onset of overt disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular (LV) enddiastolic volume, increase &gt;10%, as measured by MRI</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LV ejection fraction, absolute decrease &gt;5%, as measured by MRI</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Right ventricular (RV) enddiastolic volume, increase &gt;10%, as measured by MRI</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>RV ejection fraction, absolute decrease &gt;5%, as measured by MRI</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>late gadolinium enhancement, absolute increase &gt;5%, as measured by MRI</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ventricular premature complexes, increase &gt;100% in combination with absolute number &gt;1000/24 hrs (Holter monitoring)</measure>
    <time_frame>yearly at 0, 1, 2 and 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the occurrence of non-sustained ventricular tachycardia (Holter monitoring, exercise testing)</measure>
    <time_frame>yearly at 0, 1, 2 and 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QRS voltage, decrease &gt;25% (ECG)</measure>
    <time_frame>yearly at 0,1,2 and 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in symptoms/signs of heart failure and/or arrhythmias necessitating treatment according to the attending physician and likely due to arrhythmogenic cardiomyopathy</measure>
    <time_frame>yearly at 0,1,2 and 3 years, and possibly in between at referral</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Change in) cardiovascular death, including sudden death, likely due to arrhythmogenic cardiomyopathy</measure>
    <time_frame>yearly at 0,1,2 and 3 years, and possibly in between at referral</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>yearly at 0, 1, 2 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QRS-axis on 12-lead ECG</measure>
    <time_frame>yearly at 0,1, 2 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in conduction intervals (PR-interval, QRS-duration) on 12-lead ECG and signal averaged-ECG</measure>
    <time_frame>yearly at 0,1, 2 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in STT-segment on 12-lead ECG</measure>
    <time_frame>yearly at 0,1, 2 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of global or regional dysfunction and structural alterations on MRI</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Change in) Diagnosis of ARVC (according to task force criteria)</measure>
    <time_frame>yearly at 0,1,2 and 3 years, and possibly in between at referral</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Change in) Diagnosis of DCM</measure>
    <time_frame>yearly at 0,1,2 and 3 years, and possibly in between at referral</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in occurrence of sustained ventricular tachycardia or ventricular fibrillation</measure>
    <time_frame>yearly at 0,1,2 and 3 years, and possibly in between at referral</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Change in) hospitalization for a cardiovascular reason</measure>
    <time_frame>yearly at 0,1,2 and 3 years, and possibly in between at referral</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Phospholamban R14del Mutation-related Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone (Inspra, 50 mg for 3 years once daily) oral, film-coated tablet 50 mg for 3 years once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day</description>
    <arm_group_label>Eplerenone</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phospholamban (PLN) R14del mutation carriers

          -  Age ≥30 and ≤ 65 years

          -  New York Heart Association functional class ≤ 1

          -  LV ejection fraction ≥.45 (measured with MRI)

        Exclusion Criteria:

          -  Palpitations necessitating treatment (at the discretion of the attending physician)

          -  A diagnosis of DCM (see appendix 1). Note: regional LV wall motions abnormalities are
             acceptable.

          -  A diagnosis of ARVC (according to the task force criteria, see appendix 2)

          -  Global or regional RV dysfunction and/or structural alterations (according to task
             force criterion 1, see appendix 2).

          -  Ventricular premature complexes &gt;1000 during 24hours Holter-monitoring

          -  Non-sustained ventricular tachycardia during Holter-monitoring or exercise-testing

          -  History of sustained ventricular tachycardia or ventricular fibrillation

          -  Hypertension requiring the use of antihypertensive drugs, or when this is anticipated
             within the coming 3 years

          -  Evidence of ischemic heart disease

          -  Treatment with cardioactive medication

          -  Hyperkaliemia (serum potassium &gt;5.0 mmol/l)

          -  Severe renal dysfunction (eGFR &lt;30 ml/min/1.73 m2)

          -  Severe hepatic impairment (Child-Pugh class C)

          -  Women who are currently pregnant or report a recent pregnancy (last 60 days) or plan
             on becoming pregnant.

          -  Concomitant use of CYP3A4-inhibitors (see appendix 5)

          -  Concomitant use of NSAIDs (see appendix 5)

          -  Concomitant use of potassium sparing-agents (see appendix 5)

          -  Known intolerance or contraindication to aldosterone antagonists

          -  Participation in another drug trial in which the last dose of drug was within the past
             30 days.

          -  Contra-indications for MRI (claustrophobia, metal devices)

          -  Subjects unable or unwilling to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten van den Berg, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG, Department of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antonius ziekenhuis Sneek</name>
      <address>
        <city>Sneek</city>
        <state>Friesland</state>
        <zip>8600BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>North-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van der Zwaag PA, van Rijsingen IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, Wiesfeld AC, Cox MG, van Lochem LT, de Boer RA, Hofstra RM, Christiaans I, van Spaendonck-Zwarts KY, Lekanne dit Deprez RH, Judge DP, Calkins H, Suurmeijer AJ, Hauer RN, Saffitz JE, Wilde AA, van den Berg MP, van Tintelen JP. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012 Nov;14(11):1199-207. doi: 10.1093/eurjhf/hfs119. Epub 2012 Jul 20.</citation>
    <PMID>22820313</PMID>
  </reference>
  <reference>
    <citation>van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JD, Zwinderman AH, Pinto YM, Dit Deprez RH, Post JG, Tan HL, de Boer RA, Hauer RN, Christiaans I, van den Berg MP, van Tintelen JP, Wilde AA. Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet. 2014 Aug;7(4):455-65. doi: 10.1161/CIRCGENETICS.113.000374. Epub 2014 Jun 8.</citation>
    <PMID>24909667</PMID>
  </reference>
  <reference>
    <citation>Te Rijdt WP, Ten Sande JN, Gorter TM, van der Zwaag PA, van Rijsingen IA, Boekholdt SM, van Tintelen JP, van Haelst PL, Planken RN, de Boer RA, Suurmeijer AJH, van Veldhuisen DJ, Wilde AAM, Willems TP, van Dessel PFHM, van den Berg MP. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2018 Apr 6. doi: 10.1093/ehjci/jey047. [Epub ahead of print]</citation>
    <PMID>29635323</PMID>
  </reference>
  <reference>
    <citation>Te Rijdt WP, van Tintelen JP, Vink A, van der Wal AC, de Boer RA, van den Berg MP, Suurmeijer AJ. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology. 2016 Oct;69(4):542-50. doi: 10.1111/his.12963. Epub 2016 May 12.</citation>
    <PMID>26970417</PMID>
  </reference>
  <reference>
    <citation>Te Rijdt WP, van der Klooster ZJ, Hoorntje ET, Jongbloed JDH, van der Zwaag PA, Asselbergs FW, Dooijes D, de Boer RA, van Tintelen JP, van den Berg MP, Vink A, Suurmeijer AJH. Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovasc Pathol. 2017 Sep - Oct;30:23-26. doi: 10.1016/j.carpath.2017.05.004. Epub 2017 May 30.</citation>
    <PMID>28759816</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>M.p. van den Berg, MD, PhD, professor in Cardiology</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Phospholamban</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>Eplerenone</keyword>
  <keyword>presymptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

